Windham Venture Partners
Windham · Series A · 16 people tracked
Investment thesis
The firm leverages its extensive network across pharmaceutical, medical device, and digital health markets to identify disruptive healthcare technology companies that address unmet medical needs. The firm focuses on businesses that demonstrate the potential to transform healthcare delivery and improve patient outcomes, while prioritizing rigorous due diligence and strong risk-adjusted returns for investors.
Source: firm website, verified Jul 21, 2026.
Team · 16 people
from the firm's websiteCo-founder, general partner, and CEO of Windham Capital Partners with deep healthcare expertise. Previously VP & GM at healthcare enterprise software firm I-many, and business development analyst at Johnson & Johnson companies focused on interventional devices.
Co-founder of Windham Capital Partners with nearly three decades in billing and payments. Founded REMITCO (acquired by First Data) and Financial Telesis/CashFlex (acquired by CoreStates, now Wells Fargo). Currently leads Transactis Inc. and serves on boards including BillMyParents.
Co-founder and chairman of Windham Capital Partners. Retired as corporate vice president and general counsel of Johnson & Johnson after 30 years. Chairs the board of trustees of the Robert Wood Johnson Foundation, the third-largest U.S. foundation and largest devoted to healthcare.
Managing partner who joined Windham in 2023 overseeing all fund operations. Previously partner at Providence Ventures driving strategic growth initiatives. Has led or co-led multiple healthcare investments resulting in over $1 billion in realized value, including acquisitions by Hologic, Olympus, Stryker, and others.
Chief digital health officer of Emory Healthcare and former chief digital health officer at Mass General Brigham. Triple board-certified in internal medicine, clinical informatics, and pediatrics with 15 years of hospital medicine practice. Pursuing MBA from MIT Sloan with specialization in business analytics and artificial intelligence.
Former chief investment officer of MIT for 19 years and treasurer emeritus since 2006. Serves as director and treasurer at Beth Israel Deaconess Medical Center and trustee with investment committee chair roles at Robert Wood Johnson Foundation and Boston Children's Hospital.
Retired managing general partner of HealthCare Ventures, which strategically developed and managed over 100 companies with combined market cap exceeding $60 billion. Portfolio included Human Genome Sciences, MedImmune, Shire, and Dendreon. Previously worldwide president of Ortho Diagnostic Systems and VP at Johnson & Johnson International.
Executive vice president for research and development at UnitedHealth Group leading global R&D. Former founder and CEO of MYnetico/Alliance Health Solutions and chief medical officer at Health Partners and Frankford Health. Published researcher and frequent speaker on healthcare issues.
Founder and chief solutions officer of Helgerson Solutions Group, a healthcare consultancy focused on value-based transitions. Former Medicaid director of New York (managing $70 billion program for 7+ years) and Wisconsin, where he led the nationally recognized Badgercare Plus program.
Leading healthcare policy expert with 30+ years advising federal and state governments, health systems, health plans, and technology companies. Founder of Sachs Policy Group, a consulting firm advising healthcare leaders on policy matters.
Operations associate at Windham Capital Partners. Previously office manager and executive assistant at Interior Marketing Group, a luxury real estate design and marketing firm.
Director of marketing and business development at Windham. Co-founder and treasurer of Lynn Sage Breast Cancer Foundation and CEO of Chill Anywhere, a digital mental wellness platform. Former director of marketing and investor relations at Castle Creek Arbitrage and prior roles at JP Morgan, Credit Suisse, and CIBC.
Director of science and technology at Windham. Holds MD from University of Toronto and PhD in molecular biology. Professor emeritus at Stony Brook where he directed a medical research lab for 30 years focused on stem cells and gene/cell therapy. Authored over 60 peer-reviewed publications and received NIH MERIT award.
Associate responsible for sourcing, due diligence, and portfolio support. Previously regulatory affairs specialist at Arthrex on the founding team of their cardiothoracic unit. Also interned at LifeX, a life science and healthcare accelerator.
Executive vice president and chief strategy and digital officer at Providence, overseeing system strategy and digital innovation for an integrated delivery network of 52 hospitals and 1,085 clinics serving 5+ million patients. Architect of Digital Innovation Group fostering partnerships with 150+ health system teams and venture capital organizations.
Data scientist and investor serving as chief planning specialist of S&S Global Family Office, which invests in data science across industries. CEO of The Self Research Institute, a non-profit focused on personal informatics research. PhD candidate in personal informatics with 14 years in leadership roles.
What they invest in
from 12 of 61 portfolio companiesHealthtech ×9Biotech ×6Medical Devices ×6Digital Health ×4AI & Machine Learning ×3Enterprise Software ×2SaaS ×2FemTech ×1
HQs:United States×5
Investments · showing 60 of 61
founders shown can be your intro pathAndros provides data-driven provider network management solutions for healthcare organizations, offering strategic and execution support across the full network lifecycle. The company's platform, Andros Arc, enables health plans and providers to optimize their networks for improved care outcomes and operational efficiency.
Enterprise SoftwareHealthtechSaaS<UNKNOWN>
ChromaCode develops a High-Definition PCR (HDPCR) multiplexing platform that enables genomic solutions for oncology and precision medicine, offering faster results and cost-effective workflows through automated interpretation and cloud-based software.
AI & Machine LearningBiotechMedical Devices
CVRx develops Barostim, an implantable medical device that uses baroreceptor activation to treat heart failure patients and improve their functional capacity and quality of life.
BiotechHealthtechMedical DevicesAustin, US
Neuspera develops an integrated sacral neuromodulation system for treating urinary urge incontinence, using a smart implanted neurostimulator paired with a wireless external battery. The device is designed for women with overactive bladder symptoms.
HealthtechMedical Devices
Revelle Aesthetics develops and commercializes the Avéli device, a precision medical technology for cellulite reduction. The company serves aesthetic practitioners and women seeking non-invasive treatments for skin appearance concerns.
FemTechMedical Devices
Eb Bright(Co-Founder and Chief Administrative Officer)Jonathan Podmore(Co-Founder and Chief Technology Officer)
Science Exchange provides operational infrastructure for life sciences R&D, connecting organizations, suppliers, and workflows to streamline contracting, compliance, onboarding, and financial coordination across the research ecosystem.
BiotechEnterprise SoftwareHealthtechSaaSSan Francisco, US
Elizabeth Iorns(Founder/President & CEO; Chairman of the Board)inDan Knox(Founder & COO)inMark Layden(CEO & Chairman)
SubjectWell operates a patient network that links individuals to clinical trials and connects them with healthcare providers and pharmaceutical sponsors. The company serves patients, clinical research organizations, and pharmaceutical companies seeking to recruit and retain participants for medical studies.
BiotechDigital HealthHealthtech
Valeera Health provides virtual mental health care for adults and children, offering treatment plans developed by vetted in-house providers using data-driven clinical practices. The company delivers personalized care coordination through online appointments with a focus on accessibility and affordability.
Digital HealthHealthtechMental Health
Clever Care is a culturally and linguistically sensitive Medicare Advantage health plan serving Southern California that integrates Eastern and Western medicine approaches. It connects members with bilingual physicians, hospitals, and acupuncturists to deliver personalized care aligned with each community's cultural traditions and values.
HealthtechInsurTechSouthern California, US
Welldoc develops an AI-driven digital health platform focused on cardiometabolic disease management, providing personalized treatment solutions for patients with diabetes and related conditions. The company serves healthcare providers, health plans, and patients seeking evidence-based, technology-enabled chronic care management.
AI & Machine LearningDigital HealthHealthtechBaltimore, US
Kevin McRaith(President and CEO)Anand Iyer(Chief AI Officer)
FORE Biotherapeutics develops next-generation targeted oncology treatments, specifically plixorafenib, a novel BRAF inhibitor designed to treat patients with BRAF-altered solid tumors and other cancers. The company is a virtual biotech firm advancing plixorafenib through registration-intended clinical trials for patients with unaddressed mutations.
BiotechMedical Devices
Frequently asked questions
- What stage does Windham Venture Partners invest at?
- Windham Venture Partners invests at the Series A stage.
- What sectors does Windham Venture Partners focus on?
- Windham Venture Partners focuses on Healthtech.
- Where is Windham Venture Partners located?
- Windham Venture Partners is headquartered in Windham, US.
Similar investors
83North is a lean venture capital partnership of four equal general partners that has operated for 19 years. The firm invests globally across the US, Europe, and Israel, and in 2025 raised what it describes as its final fund, shifting focus toward selectively pursuing new opportunities while supporting existing portfolio companies.
8VC is a technology investment firm focused on building and investing in ambitious companies across life sciences, healthcare, manufacturing, enterprise, logistics, and defense sectors, with particular emphasis on operational intelligence and data-driven decision-making.
a16z is a venture capital firm founded in 2009 by Marc Andreessen and Ben Horowitz that invests in seed through growth-stage technology companies across multiple sectors including AI, healthcare, consumer, crypto, enterprise, fintech, and gaming. The firm manages over $100 billion in assets and operates a distinctive platform model with a large team of operators supporting founders throughout their journey.
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
Bessemer Venture Partners is a venture capital firm with a 50-year history supporting entrepreneurs in building enduring companies globally. The firm draws on deep operational expertise and advisory relationships to support portfolio companies through their growth journey.